METabolic EXplorer — AGM Information 2009

Jun 29, 2009

METabolic EXplorer reports on its 2009 Combined Special and Annual General Shareholders' Meeting.

Clermont-Ferrand, June 18th, 2009 – METabolic Explorer, the green chemistry company specializing in the development of bioprocesses for the production of chemical compounds used in a wide range of everyday products (paints, solvents, animal feed supplements, adhesives, textile fibres, resorbable surgical thread, etc.), has reported on its Combined Special and Annual General Shareholders' Meeting (held on June 10th, 2009, at Clermont-Ferrand International Airport (Clermont-Ferrand, France) and chaired by Professor Daniel Thomas, the Chairman of the company's Supervisory Board).

As part of the Annual General Shareholders' Meeting, the attending and proxy shareholders approved:

• the corporate accounts for 2008 in French GAAP and IFRS formats.
• the attribution of profits for the 2008 fiscal year.
• the regulated, related-party agreements covered by Article L. 225-86 of the French Commercial Code.
• the annual remuneration awarded to the members of the Supervisory Board.
• the annual remuneration awarded the members of the Supervisory Board's independent committees.

As part of the Special General Shareholders' Meeting, the shareholders adopted resolutions authorizing:

• an increase in the company's share capital by issuance of ordinary shares or any other type of security, with maintenance of preferential subscription rights and with delegation of authority to the Management Board, subject to the overall ceiling on issuances (a nominal amount of €224,180).
• an additional share capital increase, in order to protect the interests of bearers of securities giving entitlement to the company's existing share capital, with delegation of authority to the Management Board.
• an increase in the company's share capital by issuance of ordinary shares or any other type of security, with cancellation of preferential subscription rights and with delegation of authority to the Management Board.
• a delegation of authority to the Management Board for the free issue and award of 350,000 share warrants for company founders (BSPCE).
• a delegation of authority to the Management Board for the issue of 100,000 unrestricted company share warrants.
• a delegation of authority to the Management Board for the issue of share warrants enabling subscription to company shares under preferential conditions in the event of a public tender to purchase or exchange company shares, in compliance with the provisions of Article L. 233-32 II and the subsequent articles of the French Commercial Code.
• the Management Board to implement a share buy-back program covering up to 10% of the company's share capital, with respect to and in compliance with the provisions of Article L. 225-209 of the French Commercial Code and Article 241-1 and the subsequent articles of the Autorité des Marchés Financiers' General Regulations.
• the Management Board to cancel own shares acquired as part of a share buy-back program by reduction of the company's share capital, with respect to and in compliance with the

provisions of Article L. 225-209 of the French Commercial Code and Article 241-1 and the subsequent articles of the Autorité des Marchés Financiers' General Regulations.

In accordance with the Management Board's recommendations, a resolution seeking to increase the proportion of the company's equity reserved for salaried employees (according to the conditions set out in Article L. 443-5 of the French Labour Code and Article L. 225-129-6 of the French Commercial Code and with delegation of authority to the Management Board) was rejected.

Lastly, the Management Board was authorized to carry out all formalities required by law.

These decisions testify to the high degree of cohesion between METabolic Explorer's shareholders, Management Board and Supervisory Board and the common will to match the company's resources with its scheduled growth.

Next financial announcement: turnover for H1 2009, Friday July 17th, 2009, at 7.00am (Paris time).

-END-

About METabolic EXplorer - www.metabolic-explorer.com

METabolic EXplorer is a biological chemistry company which was incorporated in 1999. Its goal is to help industrial businesses deal with the heralded "end of oil" and thus continue to produce but in a sustainable way.

METabolic EXplorer leverages the tried and tested principle of industrial fermentation to provide solutions that avoid costly, burdensome petrochemical processes and are capable of using a wide range of renewable, sustainable raw materials. By optimizing the yield of non-pathogenic bacteria in a contained, controlled environment, the company helps manufacture chemical compounds that are used in everyday commodities (paints, solvents, adhesives, textile fibres, etc.) and specialized products (such as surgical thread and animal feed).

METabolic EXplorer is currently focusing its solution (based on the development of sustainable bioprocesses) on the production of 5 compounds with an estimated cumulative annual end market value of \$14 billion. This solution will be implemented worldwide via semi-exclusive industrial alliances and joint venture options with chemical industry players.

METabolic EXplorer is based in Clermont-Ferrand, France. It is listed on NYSE EURONEXT PARIS (EURONEXT C, METEX) and features in the SBF 250 and CAC Small 90 indexes.

Receive METabolic Explorer's financial information free of charge by registering at: www.metabolicexplorer.com or www.actus-finance.com.

Press Contacts

ATTITUDE Corporate

Eric de Lambert-Reiner E-mail: edelambert@attitude-corporate.com Tel.: +33 (0)1 4970 4341 / +33 (0)6 2529 0658

Emmanuelle Lapeyre E-mail: elapeyre@attitude-corporate.com Tel.: +33 (0)1 4970 4343 / +33 (06) 1588 6209

Financial contacts

METabolic EXplorer S.A.

Paul Michalet, CFO METabolic EXplorer Biopôle Clermont-Limagne F-63360 Saint-Beauzire France E-mail: infofin@metabolic-explorer.com Tel.: +33 (0)4 7333 4300 Fax: +33 (0)4 7333 4301

Actus Finance

E-mail: jfl@actus.fr Jérôme Fabreguettes-Leib Tel.: +33 (0)1 7735 0436

This communication includes forward-looking information which is subject to risks and uncertainties. The potential development of the company could be substantially different from that anticipated in this press release because of the various risk factors which are described in the company's Listing Prospectus.